Novel therapeutics and targets for the treatment of diabetes

Expert Review of Clinical Pharmacology

Volumn 3, Issue 2, 2010, Pages 209-229

  Aicher, Thomas D ^a   Boyd, Steven A ^a   McVean, Maralee ^a   Celeste, Anthony ^a  

^a ARRAY BIOPHARMA INC   (United States)

Author keywords

cell; Diabetes; Therapy; Weight loss

Indexed keywords

ANTIDIABETIC AGENT; COLESEVELAM; DAPAGLIFLOZIN; EXENDIN 4; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 120; G PROTEIN COUPLED RECEPTOR 40; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOKINASE; GLUCOSE; INSULIN; MBX 2982; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PIRAGLIATIN; PLACEBO; PRAMLINTIDE; REMOGLIFLOZIN ETABONATE; RIMONABANT; RO 28 1675; ROSIGLITAZONE; SAXAGLIPTIN; SERGLIFLOZIN ETABONATE; SITAGLIPTIN; SULFONYLUREA; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ADD ON THERAPY; APOPTOSIS; B LYMPHOCYTE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CONGESTIVE HEART FAILURE; DEPRESSION; DIABETES MELLITUS; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG WITHDRAWAL; FRACTURE; GASTROINTESTINAL TOXICITY; GENITAL TRACT INFECTION; GLUCOSE HOMEOSTASIS; GLUCOSURIA; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LACTIC ACIDOSIS; LYMPHOCYTE FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; SIDE EFFECT; URINARY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 77949355634     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.10.1     Document Type: Review

References (251)

1. Roman SH, Harris ML. Management of diabetes mellitus from a public health perspective. Endocrinol. Metab. Clin. North. Am. 26(3), 443-474 (1997).
2. Genuth S, Alberti KG, Bennett P et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26(11), 3160-3167 (2003).
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004).
4. Nathan DM, Davidson MB, DeFronzo RA et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30(3), 753-759 (2007).
5. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N. Engl. J. Med. 356(3), 213-215 (2007).
6. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. b-cell defcit and increased b-cell apoptosis in humans with Type 2 diabetes. Diabetes 52(1), 102-110 (2003).
7. Home PD, Pacini G. Hepatic dysfunction and insulin insensitivity in Type 2 diabetes mellitus: a critical target for insulin-sensitizing agents. Diabetes Obes. Metab. 10(9), 699-718 (2008).
8. DeFronzo RA. Lilly lecture 1987. The triumvirate: b-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37(6), 667-687 (1988).
9. Wasserman DH. Four grams of glucose. Am. J. Physiol. Endocrinol. Metab. 296(1), E11-E21 (2009).
10. DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of Type 2 diabetes mellitus. Diabetes 58(4), 773-795 (2009)
11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N. Engl. J. Med. 329(14), 977-986 (1993).
12. Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N. Engl. J. Med. 342(6), 381-389 (2000).
13. Martin CL, Albers J, Herman WH et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 29(2), 340-344 (2006).
14. Stratton IM, Adler AL, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321(7258), 405-412 (2000).
15. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28(2), 103-117 (1995).
16. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). UK prospective diabetes study (UKPDS) group. Lancet 352(9131), 854-865 (1998).
17. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet 352(9131), 837-853 (1998).
18. Panzram G. Mortality and survival in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30(3), 123-131 (1987).
19. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 241(19), 2035-2038 (1979).
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19), 2486-2497 (2001).
21. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald A P, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 41(6), 736-741 (1992).
22. Alzaid AA. Microalbuminuria in patients with NIDDM: an overview. Diabetes Care 19(1), 79-89 (1996).
23. Nelson RG, Pettitt DJ, Carraher MJ, Baird HR, Knowler WC. Effect of proteinuria on mortality in NIDDM. Diabetes 37(11), 1499-1504 (1988).
24. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44(11), 1303-1309 (1995).
25. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with Type diabetes. N. Engl. J. Med. 353(25), 2643-2653 (2005).
26. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med. 359(15), 1577-1589 (2008).
27. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with Type 2 diabetes. N. Engl. J. Med. 360(2), 129-139 (2009).
28. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358(24), 2545-2559 (2008).
29. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356(24), 2457-2471 (2007).
30. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann. Intern. Med. 147(8), 578-581 (2007).
31. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1), 193-203 (2009).
32. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 32(Suppl. 1), S13-S61 (2009).
33. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr. Rev. 19(5), 608-624 (1998).
34. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes. Metab. 9(6), 799-812 (2007).
35. Snoek FJ. Breaking the barriers to optimal glycaemic control-what physicians need to know from patients' perspectives. Int. J. Clin. Pract. Suppl. 129, 80-84 (2002).
36. Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobson AM, Cole CF. Insulin omission in women with IDDM. Diabetes Care 17(10), 1178-1185 (1994).
37. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with Type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 26(1), 138-143 (2003).
38. Ratner RE, Dickey R, Fineman M et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet. Med. 21(11), 1204-1212 (2004).
39. 1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with Type 1 diabetes approaching glycemic targets. Exp. Clin. Endocrinol. Diabetes 113(4), 199-204 (2005).
40. Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C. Physical activity/ exercise and Type 2 diabetes. Diabetes Care 27(10), 2518-2539 (2004).
41. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108(8), 1167-1174 (2001).
42. Musi N, Hirshman MF, Nygren J et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with Type 2 diabetes. Diabetes 51(7), 2074-2081 (2002).
43. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev. 6, 89-131 (1998).
44. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with Type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK prospective diabetes study (UKPDS) group. JAMA 281(21), 2005-2012 (1999).
45. Dodge JA, Richardson TL. Novel selective estrogen receptor modulators (SERMs). In: Annual Reports in Medicinal Chemistry (Volume 42). Macor JE (Ed.). Academic Press, NY, USA 147-160 (2007).
46. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA. Corepressors selectively control the transcriptional activity of PPARg in adipocytes. Genes Dev. 19(4), 453-461 (2005).
47. Lemay DG, Hwang DH. Genome-wide identifcation of peroxisome proliferator response elements using integrated computational genomics. J. Lipid Res. 47(7), 1583-1587 (2006).
48. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298(10), 1189-1195 (2007).
49. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet 366(9493), 1279-1289 (2005).
50. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298(10), 1180-1188 (2007).
51. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve b-cell function in Type 2 diabetic patients. Am. J. Physiol. Endocrinol. Metab. 292(3), E871-E883 (2007).
52. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch. Intern. Med. 168(8), 820-825 (2008).
53. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fuid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27(1), 256-263 (2004).
54. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in Type 2 diabetes mellitus. Drug Saf. 30(12), 1127-1142 (2007).
55. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N. Engl. J. Med. 357(1), 28-38 (2007).
56. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 30(8), 2148-2153 (2007).
57. Kintscher U. Pharmacological differences of glitazones: does peroxisome proliferator-activated receptor-g activation make the difference? J. Am. Coll. Cardiol. 52(10), 882-884 (2008).
58. Cho N, Momose Y. Peroxisome proliferator-activated receptor g agonists as insulin sensitizers: from the discovery to recent progress. Curr. Top. Med. Chem. 8(17), 1483-1507 (2008).
59. Balint BL, Nagy L. Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases. Endocr. Metab. Immune Disord. Drug Targets 6(1), 33-43 (2006).
60. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Effcacy and safety of colesevelam in patients with Type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch. Intern. Med. 168(14), 1531-1540 (2008).
61. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled Type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31(8), 1479-1484 (2008).
62. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with Type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch. Intern. Med. 168(18), 1975-1983 (2008).
63. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of welchol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with Type 2 diabetes. Clin. Ther. 29(1), 74-83 (2007).
64. Shang Q, Saumoy M, Holst JJ, Salen G, Xu G. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model. Presented at: 69th Scientifc Sessions of the American Diabetes Association. New Orleans, LA, USA, 5-9 June 2009.
65. Jones MR, Mudaliar S, Hernandez-Triana E et al. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as frst-line therapy in Type 2 diabetes and colesevelam HCl in prediabetes. Curr. Med. Res. Opin. 25(9), 2239-2249 (2009).
66. Blickle JF. Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab. 32(2), 113-120 (2006).
67. Aguilar-Bryan L, Nichols CG, Wechsler SW et al. Cloning of the b cell high-affnity sulfonylurea receptor: a regulator of insulin secretion. Science 268(5209), 423-426 (1995).
68. Ashcroft FM. Mechanisms of the glycaemic effects of sulfonylureas. Horm. Metab. Res. 28(9), 456-463 (1996).
69. Rustenbeck I, Wienbergen A, Bleck C, Jorns A. Desensitization of insulin secretion by depolarizing insulin secretagogues. Diabetes 53(Suppl. 3), S140-S150 (2004).
70. Tan MH, Baksi A, Krahulec B et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with Type 2 diabetes. Diabetes Care 28(3), 544-550 (2005).
71. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355(23), 2427-2443 (2006).
72. Hanefeld M, Pfutzner A, Forst T, Lubben G. Glycemic control and treatment failure with pioglitazone versus glibenclamide in Type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr. Med. Res. Opin. 22(6), 1211-1215 (2006).
73. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced b-cell apoptosis in cultured human islets. J. Clin. Endocrinol. Metab. 90(1), 501-506 (2005).
74. Takahashi A, Nagashima K, Hamasaki A et al. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic b-cell death in the chronic phase. Diabetes Res. Clin. Pract. 77(3), 343-350 (2007).
75. Qian L, Zhang S, Xu L, Peng Y. Endoplasmic reticulum stress in b cells: latent mechanism of secondary sulfonylurea failure in Type 2 diabetes? Med. Hypotheses 71(6), 889-891 (2008).
76. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr. Rev. 29(1), 42-61 (2008).
77. Yamada T, Ishihara H, Tamura A et al. WFS1-defciency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway specifcally in pancreatic b-cells. Hum. Mol. Genet. 15(10), 1600-1609 (2006).
78. Fonseca SG, Fukuma M, Lipson KL et al. WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic b-cells. J. Biol. Chem. 280(47), 39609-39615 (2005).
79. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of Type 2 diabetes. Nat. Rev. Drug Discov. 8(5), 369-385 (2009).
80. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr. Rev. 20(6), 876-913 (1999).
81. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326(20), 1316-1322 (1992).
82. Turton MD, O'Shea D, Gunn I et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379(6560), 69-72 (1996).
83. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia 29(1), 46-52 (1986).
84. Lyssenko V, Lupi R, Marchetti P et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of Type 2 diabetes. J. Clin. Invest. 117(8), 2155-2163 (2007).
85. Wajcberg E, Tavaria A. Exenatide: clinical aspects of the frst incretin-mimetic for the treatment of Type 2 diabetes mellitus. Expert Opin. Pharmacother. 10(1), 135-142 (2009).
86. Malone J, Trautmann M, Wilhelm K, Taylor K, Kendall DM. Exenatide once weekly for the treatment of Type 2 diabetes. Expert Opin. Investig. Drugs 18(3), 359-367 (2009).
87. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for Type 2 diabetes (lead-3 mono): a randomised, 52-week, Phase III, double-blind, parallel-treatment trial. Lancet 373(9662), 473-481 (2009).
88. Campas C, Castaner R. AVE-0010. Drugs Future 33(10), 838-840 (2008).
89. Retterstol K. Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue. Expert Opin. Investig. Drugs 18(9), 1405-1411 (2009).
90. Matthews JE, Stewart MW, de Boever EH et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 93(12), 4810-4817 (2008).
91. Zerilli T, Pyon EY. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of Type 2 diabetes mellitus. Clin. Ther. 29(12), 2614-2634 (2007).
92. Gallwitz B. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes. IDrugs 11(12), 906-917 (2008).
93. Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of Type 2 diabetes mellitus. Drugs 68(16), 2387-2409 (2008).
94. Gupta R, Walunj SS, Tokala RK, Parsa K V, Singh SK, Pal M. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 diabetes. Curr. Drug Targets 10(1), 71-87 (2009).
95. Ahren B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin. Emerg. Drugs 13(4), 593-607 (2008).
96. Kim SJ, Nian C, Widenmaier S, McIntosh CH. Glucose-dependent insulinotropic polypeptide-mediated up-regulation of b-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol. Cell. Biol. 28(5), 1644-1656 (2008).
97. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both b-cell replication and neogenesis, resulting in increased b-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48(12), 2270-2276 (1999).
98. Stoffers DA, Kieffer TJ, Hussain MA et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49(5), 741-748 (2000).
99. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of Type 2 diabetes in the Goto-Kakizaki rat model by expansion of the b-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51(5), 1443-1452 (2002).
100. Mu J, Woods J, Zhou YP et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic b-cell mass and function in a rodent model of Type 2 diabetes. Diabetes 55(6), 1695-1704 (2006).
101. Pospisilik JA, Martin J, Doty T et al. Dipeptidyl peptidase IV inhibitor treatment stimulates b-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52(3), 741-750 (2003).
102. Liu Z, Habener JF. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic b-cell proliferation. J. Biol. Chem. 283(13), 8723-8735 (2008).
103. Scherbaum WA, Schweizer A, Mari A et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with Type 2 diabetes and mild hyperglycaemia. Diabetes Obes. Metab. 10(11), 1114-1124 (2008).
104. Chu ZL, Jones RM, He H et al. A role for b-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 148(6), 2601-2609 (2007).
105. Chu ZL, Carroll C, Alfonso J et al. A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149(5), 2038-2047 (2008).
106. Soga T, Ohishi T, Matsui T et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem. Biophys. Res. Commun. 326(4), 744-751 (2005).
107. Lauffer LM, Iakoubov R, Brubaker PL. Gpr119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58(5), 1058-1066 (2009).
108. Parker HE, Habib AM, Rogers GJ, Gribble FM, Reimann F. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52(2), 289-298 (2009).
109. Fredriksson R, Hoglund PJ, Gloriam DE et al. Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. FEBS Lett. 554(3), 381-388 (2003).
110. Overton HA, Babbs AJ, Doel SM et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 3(3), 167-175 (2006).
111. Jones RM, Leonard JN, Buzard DJ, Lehmann J. GPR119 agonists for the treatment of Type 2 diabetes. Expert Opin. Ther. Pat. 19(10), 1339-1359 (2009).
112. Carpenter A, Ammala C, Briscoe C et al. The in vitro and in vivo effects of a GPR119 agonist. Presented at: Keystone Symposia: Diabetes Mellitus, Insulin Action and Resistance. Breckenridge, CO, USA, 22-27 June 2008.
113. Ammala C, Bullard S, Kashatus J et al. GPR119 dependent hormone secretion: insulin GLP-1 and more. Presented at: 68th Scientifc Sessions of the American Diabetes Association. San Francisco, CA, USA, 6-10 June 2008.
114. Semple G, Fioravanti B, Pereira G et al. Discovery of the frst potent and orally effcacious agonist of the orphan G-protein coupled receptor 119. J. Med. Chem. 51(17), 5172-5175 (2008).
115. Overton HA, Fyfe MC, Reynet C. GPR119, a novel G protein-coupled receptor target for the treatment of Type 2 diabetes and obesity. Br. J. Pharmacol. 153(Suppl. 1), S76-S81 (2008).
116. Fyfe A, White J, Widdowson P, Overton H, Reynet C. GPR119 agonists are potential novel oral agents for the treatment of diabesity. Presented at: 67th Scientifc Sessions of the American Diabetes Association. Chicago, IL, USA, 22-26 June 2007.
117. Fyfe A, McCormack J, Overton H, Procter M, Reynet C. PSN821: a novel oral GPR119 agonist for the treatment of Type 2 diabetes producing substantial glucose lowering and weight loss in rats. Presented at: 68th Scientifc Sessions of the American Diabetes Association. San Francisco, CA, USA, 6-10 June 2008.
118. Wilson M, Gregoire F, Pandey B et al. GPR119 agonists acutely improve glycemia in rodents by delaying gastric emptying, increasing incretin levels and directly stimulating insulin secretion, and delay diabetes onset in female ZDF rats during chronic treatment. Presented at: Keystone Symposium: Type 2 Diabetes and Insulin Resistance. Banff, AB, Canada, 20-25 January 2009.
119. Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol. Sci. DOI: 10.1016/j.plipres.2009.11.001 (2009) (Epub ahead of print).
120. Reimann F, Habib AM, Tolhurst G et al. Glucose sensing in L cells: a primary cell study. Cell Metab. 8(6), 532-539 (2008).
121. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun. 329(1), 386-390 (2005).
122. Kawamata Y, Fujii R, Hosoya M et al. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278(11), 9435-9440 (2003).
123. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J. Clin. Invest. 116(10), 2571-2579 (2006).
124. Watanabe M, Houten SM, Mataki C et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439(7075), 484-489 (2006).
125. Malm J. Thyroid hormone ligands and metabolic diseases. Curr. Pharm. Des. 10(28), 3525-3532 (2004).
126. Yokoyama N, Walker GN, Main AJ et al. Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine. J. Med. Chem. 38(4), 695-707 (1995).
127. Thomas C, Gioiello A, Noriega L et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10(3), 167-177 (2009).
128. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr. Rev. 23(1), 38-89 (2002).
129. Winzell MS, Ahren B. G-protein-coupled receptors and islet function-implications for treatment of Type 2 diabetes. Pharmacol. Ther. 116(3), 437-448 (2007).
130. Hirasawa A, Hara T, Katsuma S, Adachi T, Tsujimoto G. Free fatty acid receptors and drug discovery. Biol. Pharm. Bull. 31(10), 1847-1851 (2008).
131. Costanzi S, Neumann S, Gershengorn MC. Seven transmembrane-spanning receptors for free fatty acids as therapeutic targets for diabetes mellitus: pharmacological, phylogenetic, and drug discovery aspects. J. Biol. Chem. 283(24), 16269-16273 (2008).
132. Bharate SB, Nemmani KV, Vishwakarma RA. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for Type 2 diabetes. Expert Opin. Ther. Pat. 19(2), 237-264 (2009).
133. Briscoe CP, Tadayyon M, Andrews JL et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem. 278(13), 11303-11311 (2003).
134. Flodgren E, Olde B, Meidute-Abaraviciene S, Winzell MS, Ahren B, Salehi A. GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem. Biophys. Res. Commun. 354(1), 240-245 (2007).
135. Nagasumi K, Esaki R, Iwachidow K et al. Overexpression of GPR40 in pancreatic b-cells augments GSIS and improves glucose tolerance in normal and diabetic mice. Diabetes 58(5), 1067-1076 (2009).
136. Alquier T, Poitout V. GPR40: good cop, bad cop? Diabetes 58(5), 1035-1036 (2009).
137. Rayasam GV, Tulasi VK, Davis JA, Bansal VS. Fatty acid receptors as new therapeutic targets for diabetes. Expert Opin. Ther. Targets 11(5), 661-671 (2007).
138. Hirasawa A, Tsumaya K, Awaji T et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 11(1), 90-94 (2005).
139. Cornish J, MacGibbon A, Lin JM et al. Modulation of osteoclastogenesis by fatty acids. Endocrinology 149(11), 5688-5695 (2008).
140. Suzuki T, Igari S, Hirasawa A et al. Identifcation of G protein-coupled receptor 120-selective agonists derived from PPAR-g agonists. J. Med. Chem. 51(23), 7640-7644 (2008).
141. Hara T, Hirasawa A, Sun Q et al. Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn Schmiedebergs Arch. Pharmacol. 380(3), 247-255 (2009).
142. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat. Rev. Drug Discov. 8(5), 399-416 (2009).
143. Coghlan M, Leighton B. Glucokinase activators in diabetes management. Expert Opin. Investig. Drugs 17(2), 145-167 (2008).
144. Pal M. Recent advances in glucokinase activators for the treatment of Type 2 diabetes. Drug Discov. Today 14(15-16), 784-792 (2009).
145. Sarabu R, Berthel SJ, Kester RF, Tilley JW. Glucokinase activators as new Type 2 diabetes therapeutic agents. Expert Opin. Therap. Patents 18(7), 759-768 (2008).
146. Grimsby J, Berthel SJ, Sarabu R. Glucokinase activators for the potential treatment of Type 2 diabetes. Curr. Top. Med. Chem. 8(17), 1524-1532 (2008).
147. Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 12(3), 429-438 (2004).
148. Grimsby J, Sarabu R, Corbett WL et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301(5631), 370-373 (2003).
149. McKerrecher D, Allen JV, Bowker SS et al. Discovery, synthesis and biological evaluation of novel glucokinase activators. Bioorg. Med. Chem. Lett. 15(8), 2103-2106 (2005).
150. Coope GJ, Atkinson AM, Allott C et al. Predictive blood glucose lowering effcacy by glucokinase activators in high fat fed female Zucker rats. Br. J. Pharmacol. 149(3), 328-335 (2006).
151. Johnson D, Shepherd RM, Gill D, Gorman T, Smith DM, Dunne MJ. Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50, a glucokinase activator. Diabetes 56(6), 1694-1702 (2007).
152. Leighton B, Atkinson AM, Coope GJ, Coghlan MP. Improved glycemic control after sub-acute administration of a glucokinase activator to male Zucker (fa/fa) rats. Presented at: 67th Scientifc Sessions of the American Diabetes Association. Chicago, IL, USA, 22-26 June 2007.
153. Efanov AM, Barrett DG, Brenner MB et al. A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology 146(9), 3696-3701 (2005).
154. Castelhano AL, Dong H, Fyfe MC et al. Glucokinase-activating ureas. Bioorg. Med. Chem. Lett. 15(5), 1501-1504 (2005).
155. Fyfe MC, White JR, Taylor A et al. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia 50(6), 1277-1287 (2007).
156. Bertram LS, Black D, Briner PH et al. SAR, pharmacokinetics, safety, and effcacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1. J. Med. Chem. 51(14), 4340-4345 (2008).
157. Futamura M, Hosaka H, Kadotani A et al. An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J. Biol. Chem. 281(49), 37668-37674 (2006).
158. Iino T, Sasaki Y, Bamba M et al. Discovery and structure-activity relationships of a novel class of quinazoline glucokinase activators. Bioorg. Med. Chem. Lett. 19(19), 5531-5538 (2009).
159. Takahashi K, Hashimoto N, Nakama C et al. The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators. Bioorg. Med. Chem. 17(19), 7042-7051 (2009).
160. Boyd SA. ARRY-588 and ARRY-403: novel glucokinase activators with potent glucose-lowering activity in animal models of Type 2 diabetes mellitus. Presented at: SMI Metabolic Diseases Conference. London, UK, 26 September 2008.
161. Aicher TD, Anderson D, Boyd SA et al. ARRY-403, a novel glucokinase activator with potent glucose-dependent anti-hyperglycemic activity in animal models of Type 2 diabetes mellitus. Presented at: Keystone Symposium: Type 2 Diabetes and Insulin Resistance. Banff, AB, Canada, 20-25 January 2009.
162. McVean M, Aicher TD, Boyd SA et al. Combination therapy of ARRY-403 with metformin, sitagliptin, or pioglitazone results in additive glucose lowering in female ZDF rats. Presented at: Keystone Symposium: Type 2 Diabetes and Insulin Resistance. Banff, AB, Canada, 20-25 January 2009.
163. Bebernitz GR, Beaulieu V, Dale BA et al. Investigation of functionally liver selective glucokinase activators for the treatment of Type 2 diabetes. J. Med. Chem. 52(19), 6142-6152 (2009).
164. Van Poelje PD, Dang Q, Erion MD. Discovery of fructose-1,6-bisphosphatase inhibitors for the treatment of Type 2 diabetes. Curr. Opin. Drug Discov. Devel. 10(4), 430-437 (2007).
165. Tejwani GA. Regulation of fructose-bisphosphatase activity. Adv. Enzymol. Relat. Areas Mol. Biol. 54, 121-194 (1983).
166. Dang Q, Kasibhatla SR, Reddy KR et al. Discovery of potent and specifc fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of Type 2 diabetes. J. Am. Chem. Soc. 129(50), 15491-15502 (2007).
167. Van Poelje PD, Potter SC, Fujitaki JM et al. MB07803, a prodrug of a second generation fructose-1,6-bisphosphatase inhibitor, lowers blood glucose in diabetic rodents and in cynomolgus monkeys. Presented at: 68th Scientifc Sessions of the American Diabetes Association. San Francisco, CA, USA, 6-10 June 2008.
168. Erion MD, Van Poelje PD, Dang Q et al. MB06322 (CS-917): a potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in Type 2 diabetes. Proc. Natl Acad. Sci. USA 102(22), 7970-7975 (2005).
169. Van Poelje PD, Potter SC, Chandramouli VC, Landau BR, Dang Q, Erion MD. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in zucker diabetic fatty rats. Diabetes 55(6), 1747-1754 (2006).
170. Gumbiner B. Pronounced glucose reduction in poorly controlled T2DM with MB07803, a novel fructose-1,6-bisphosphatase inhibitor (FBPase) with reduced potential for acid-base disturbances vs the 1st generation FBPaseI CS-917. Presented at: 69th Scientifc Sessions of the American Diabetes Association. New Orleans, LA, USA, 5-9 June 2009.
171. Washburn WN. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus Type 2. J. Med. Chem. 52(7), 1785-1794 (2009).
172. Washburn WN. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents. Expert Opin. Ther. Pat. 19(11), 1485-1499 (2009).
173. +/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J. Clin. Invest. 93(1), 397-404 (1994).
174. Thorens B. Glucose transporters in the regulation of intestinal, renal, and liver glucose fuxes. Am. J. Physiol. 270(4 Pt 1), G541-G553 (1996).
175. Rahmoune H, Thompson PW, Ward JM et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54(12), 3427-3434 (2005).
176. Van Den Heuvel LP, Assink K, Willemsen M, Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum. Genet. 111(6), 544-547 (2002).
177. Katsuno K, Fujimori Y, Takemura Y et al. Serglifozin, a novel selective inhibitor of low-affnity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J. Pharmacol. Exp. Ther. 320(1), 323-330 (2007).
178. Fujimori Y, Katsuno K, Ojima K et al. Serglifozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur. J. Pharmacol. 609(1-3), 148-154 (2009).
179. Katsuno K, Fujimori Y, Ishikawa-Takemura Y, Isaji M. Long-term treatment with serglifozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur. J. Pharmacol. 618(1-3), 98-104 (2009).
180. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remoglifozin etabonate, in a novel category of selective low-affnity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic effcacy in rodent models. J. Pharmacol. Exp. Ther. 327(1), 268-276 (2008).
181. Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapaglifozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of Type 2 diabetes. J. Med. Chem. 51(5), 1145-1149 (2008).
182. Han S, Hagan DL, Taylor JR et al. Dapaglifozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57(6), 1723-1729 (2008).
183. Komoroski B, Vachharajani N, Boulton D et al. Dapaglifozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin. Pharmacol. Ther. 85(5), 520-526 (2009).
184. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfster M. Dapaglifozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with Type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85(5), 513-519 (2009).
185. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapaglifozin in Type 2 diabetes. Diabetes Care 32(4), 650-657 (2009).
186. Ribera MC, Pascual R, Orozco D, Perez Barba C, Pedrera V, Gil V. Incidence and risk factors associated with urinary tract infection in diabetic patients with and without asymptomatic bacteriuria. Eur. J. Clin. Microbiol. Infect. Dis. 25(6), 389-393 (2006).
187. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapaglifozin in patients with Type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32(9), 1656-1662 (2009).
188. Farrell TM, Haggerty SP, Overby DW, Kohn GP, Richardson WS, Fanelli RD. Clinical application of laparoscopic bariatric surgery: an evidence-based review. Surg. Endosc. 23(5), 930-949 (2009).
189. Buchwald H, Estok R, Fahrbach K et al. Weight and Type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am. J. Med. 122(3), 248-256 (2009).
190. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the Rio-Europe study. Lancet 365(9468), 1389-1397 (2005).
191. 2c receptor agonist for the treatment of obesity. J. Med. Chem. 51(2), 305-313 (2008).
192. Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in Type 2 diabetic patients. J. Clin. Endocrinol. Metab. 87(6), 2784-2791 (2002).
193. Yamauchi T, Kamon J, Waki H et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor-g (PPARg) defciency and PPARg agonist improve insulin resistance. J. Biol. Chem. 276(44), 41245-41254 (2001).
194. Matsuda D, Tomoda H. DGAT inhibitors for obesity. Curr. Opin. Investig. Drugs 8(10), 836-841 (2007).
195. Smith SJ, Cases S, Jensen DR et al. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT. Nat. Genet. 25(1), 87-90 (2000).
196. Chen HC, Smith SJ, Ladha Z et al. Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. J. Clin. Invest. 109(8), 1049-1055 (2002).
197. Zhao G, Souers AJ, Voorbach M et al. Validation of diacyl glycerolacyltransferaseI as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J. Med. Chem. 51(3), 380-383 (2008).
198. Birch AM, Birtles S, Buckett LK et al. Discovery of a potent, selective, and orally effcacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor. J. Med. Chem. 52(6), 1558-1568 (2009).
199. Linders JTM, Roevens P, Berwaer M et al. Discovery, synthesis, and in vivo activity of phenylpiperazine DGAT-1 inhibitors for the treatment of metabolic syndrome. Presented at: 238th ACS National Meeting and Exposition. Washington, DC, USA, 16-20 August 2009.
200. Fox BM, Iio K, Li K et al. Discovery of pyrrolopyridazines as novel DGAT1 inhibitors. Presented at: 237th ACS National Meeting and Exposition. Salt Lake City, UT, USA, 22-26 March 2009.
201. Boyle CD. Recent advances in the discovery of 11b-HSD1 inhibitors. Curr. Opin. Drug Discov. Devel. 11(4), 495-511 (2008).
202. Boyle CD, Kowalski TJ. 11b-hydroxysteroid dehydrogenase Type 1 inhibitors: a review of recent patents. Expert Opin. Ther. Pat. 19(6), 801-825 (2009).
203. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet 367(9522), 1605-1617 (2006).
204. Hawkins M, Hunter D, Kishore P et al. INCB013739, a selective inhibitor of 11b-hydroxysteroid dehydrogenase Type 1 (11bHSD1), improves insulin sensitivity and lowers plasma cholesterol over 28 days in patients with Type 2 diabetes mellitus. Presented at: 68th Scientifc Sessions of the American Diabetes Association. San Francisco, CA, USA, 6-10 June 2008.
205. Rosenstock J, Banarer S, Fonseca V et al. Effcacy and safety of the 11b-HSD1 inhibitor INCB13739, added to metformin therapy in patients with Type 2 diabetes. Presented at: 69th Scientifc Sessions of the American Diabetes Association. New Orleans, LA, USA, 5-9 June 2009.
206. Osborne TF. Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. J. Biol. Chem. 275(42), 32379-32382 (2000).
207. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89(3), 331-340 (1997).
208. Goldstein JL, Debose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 124(1), 35-46 (2006).
209. Grand-Perret T, Bouillot A, Perrot A, Commans S, Walker M, Issandou M. SCAP ligands are potent new lipid-lowering drugs. Nat. Med. 7(12), 1332-1338 (2001).
210. Kamisuki S, Mao Q, Abu-Elheiga L et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem. Biol. 16(8), 882-892 (2009).
211. Nagle CA, An J, Shiota M et al. Hepatic overexpression of glycerol-sn-3-phosphate acyltransferase 1 in rats causes insulin resistance. J. Biol. Chem. 282(20), 14807-14815 (2007).
212. Neschen S, Morino K, Hammond LE et al. Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell Metab. 2(1), 55-65 (2005).
213. Liu G. Stearoyl-CoA desaturase inhibitors: update on patented compounds. Expert Opin. Ther. Pat. 19(9), 1169-1191 (2009).
214. Yen CL, Cheong ML, Grueter C et al. Defciency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding. Nat. Med. 15(4), 442-446 (2009).
215. Woods SC, Lutz TA, Geary N, Langhans W. Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos. Trans. R Soc. Lond. B Biol. Sci. 361(1471), 1219-1235 (2006).
216. Geary N, Kissileff HR, Pi-Sunyer FX, Hinton V. Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. Am. J. Physiol. 262(6 Pt 2), R975-R980 (1992).
217. Geary N. Pancreatic glucagon signals postprandial satiety. Neurosci. Biobehav. Rev. 14(3), 323-338 (1990).
218. Geary N. Glucagon and the control of meal size. In: Satiation: From Gut to Brain. Smith GP (Ed.). Oxford Press, NY, USA, 164-167 (1998).
219. Heckemeyer CM, Barker J, Duckworth WC, Solomon SS. Studies of the biological effect and degradation of glucagon in the rat perifused isolated adipose cell. Endocrinology 113(1), 270-276 (1983).
220. Holst JJ, Sorensen TL, Andersen AN et al. Plasma enteroglucagon after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio. Scand. J. Gastroenterol. 14(2), 205-207 (1979).
221. Wynne K, Park AJ, Small CJ et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54(8), 2390-2395 (2005).
222. Druce MR, Minnion JS, Field BC et al. Investigation of structure-activity relationships of oxyntomodulin (Oxm) using Oxm analogs. Endocrinology 150(4), 1712-1722 (2009).
223. Pocai A, Carrington PE, Adams JR et al. Glucagon and glucagon-like peptide 1 receptors in the regulation of energy homeostasis. Presented at: Keystone Symposium: Obesity: Novel Aspects of the Regulation of Weight. Banff, AB, Canada, 20-25 January 2009.
224. Day J W, Ottaway N, Patterson JT et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 5, 749-757 (2009).
225. Sinz C, Bittner A, Kim A et al. Discovery of 2-acylindoles as potent, orally active human glucagon receptor antagonists. Presented at: 235th ACS National Meeting and Exposition. New Orleans, LA, USA, 6-10 April 2008.
226. Madsen P, Kodra JT, Behrens C et al. Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties. J. Med. Chem. 52(9), 2989-3000 (2009).
227. Baggio LL, Drucker DJ. Therapeutic approaches to preserve islet mass in Type 2 diabetes. Annu. Rev. Med. 57, 265-281 (2006).
228. Meier JJ, Butler AE, Saisho Y et al. b-cell replication is the primary mechanism subserving the postnatal expansion of b-cell mass in humans. Diabetes 57(6), 1584-1594 (2008).
229. Menge BE, Tannapfel A, Belyaev O et al. Partial pancreatectomy in adult humans does not provoke b-cell regeneration. Diabetes 57(1), 142-149 (2008).
230. Lee HC, Bonner-Weir S, Weir GC, Leahy JL. Compensatory adaption to partial pancreatectomy in the rat. Endocrinology 124(3), 1571-1575 (1989).
231. Peshavaria M, Larmie BL, Lausier J et al. Regulation of pancreatic b-cell regeneration in the normoglycemic 60% partial-pancreatectomy mouse. Diabetes 55(12), 3289-3298 (2006).
232. Vidal-Alabro A, Gomez-Valades AG, Mendez-Lucas A et al. Liver GKA456V overexpression: a model for the GK activators effects on liver metabolism. Presented at: Keystone Symposium: Type 2 Diabetes and Insulin Resistance. Banff, AB, Canada, 20-25 January 2009.
233. Kester RF, Sarabu R, Corbett WL et al. Discovery of an allosteric activator of glucokinase. Presented at: 237th ACS National Meeting and Exposition. Salt Lake City, UT, USA, 22-26 March 2009.
234. Kester R F, Corbett WL, Sarabu R et al. Discovery of piragliatin, a small molecule activator of GK. Presented at: 238th ACS National Meeting and Exposition. Washington, DC, USA, 16-20 August 2009.
235. Migoya EM, Miller J, Maganti L, Gottesdeiner K, Wagner J. The glucokinase (GK) activator MK-0599 lowers plasma glucose concentrations in healthy non-diabetic subjects. Presented at: American Diabetes Association 69th Scientifc Sessions. New Orleans, LA, USA, 5-9 June 2009.
236. Hinklin RJ, Aicher TD, Boyd SA et al. ARRY-403, a glucokinase activator with potent glucose-dependent anti-hyperglycemic activity in animal models of Type 2 diabetes mellitus: frst-in-patient clinical results. Presented at: 45th Annual Meeting of the European Association for the Study of Diabetes. Vienna, Austria, 29 September-2 October 2009.
237. Hussey EK, Clark RV, Amin DM et al. Early clinical studies to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of serglifozin, a novel inhibitor of renal glucose reabsorption, in healthy volunteers and subjects with Type 2 diabetes mellitus. Presented at: 67th Scientifc Sessions of the American Diabetes Association. Chicago, IL, USA, 22-27 June 2007.
238. Hussey EK, Dobbins RL, Stolz RR et al. A double-blind randomized repeat dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of three times daily dosing of serglifozin, a novel inhibitor of renal glucose reabsorption, in healthy overweight and obese subjects. Presented at: 67th Scientifc Sessions of the American Diabetes Association. Chicago, IL, USA, 22-27 June 2007.
239. Hussey EK, Kapur A, O'Conner-Semmes RL et al. Safety, pharmokinetics and pharmacodynamics of remoglifozzin etabonate (SGLT2 inhibitor) and metformin when co-administered in Type 2 diabetes mellitus (T2DM) patients. Presented at: 69th Scientifc Sessions of the American Diabetes Association. New Orleans, LA, USA, 5-9 June 2009.
240. Dobbins RL, Kapur A, Kapitza C et al. Remoglifozzin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), reduces serum glucose in Type 2 diabetes mellitus (T2DM) patients. Presented at: 69th Scientifc Sessions of the American Diabetes Association. New Orleans, LA, USA, 5-9 June 2009.
241. Mezzetti A, Ellis G, Souhami E et al. A dose ranging study with the SGLT2 inhibitor AVE2268 in Type 2 diabetes. Presented at: 13th Proceedings of the International Congress of Endocrinology. Rio de Janeiro, Brazil, 8-12 November 2008.
242. Grempler R, Thomas L, Eckhardt M et al. In vitro properties and in vivo effect on urinary glucose excretion of BI 10773, a novel selective SGLT2 inhibitor. Presented at: 69th Scientifc Sessions of the American Diabetes Association. New Orleans, LA, USA, 5-9 June 2009.
243. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Effcacy and tolerability of rimonabant in overweight or obese patients with Type 2 diabetes: a randomised controlled study. Lancet 368(9548), 1660-1672 (2006).
244. Wadden T, Klein S, Greenway FL et al. Naltrexone + bupropion combination causes signifcant weight loss: a 56-week Phase 3 study. Presented at: 69th Scientifc Sessions of the American Diabetes Association. New Orleans, LA, USA, 5-9 June 2009.
245. Klein S, Wadden T, Erickson J et al. Naltrexone + bupropion combination causes signifcant weight loss without worsening psychiatric symptoms. Presented at: 69th Scientifc Sessions of the American Diabetes Association. New Orleans, LA, USA, 5-9 June 2009.
246. Wadden T, Pi-Sunyer FX, Erickson J et al. Naltrexone + bupropion combination causes weight loss and improves quality of life. Presented at: 69th Scientifc Sessions of the American Diabetes Association. New Orleans, LA, USA, 5-9 June 2009.
247. Garvey W T, Troupin B, Tam P et al. One-year treatment with VI-0521 in Type 2 diabetes demonstrates continued glycemic improvement and weight loss. Presented at: 69th Scientifc Sessions of the American Diabetes Association. New Orleans, LA, USA, 5-9 June 2009.
248. Dow R. Discovery of PF-04620110: a selective DGAT-1 inhibitor for the treatment of Type 2 diabetes. Presented at: Metabolic Diseases Drug Discovery & Development. Half Moon Bay, CA, USA, 22-23 September 2009.
249. Fotsch C, Adams J, Bartberger M et al. Discovery of AMG 221: an 11b-HSD1 inhibitor in the clinic for Type 2 diabetes. Presented at: 238th ACS National Meeting and Exposition. Washington, DC, USA, 16-20 August 2009.
250. Caille S, Cui S, Hwang TL, Wang X, Faul MM. Two asymmetric syntheses of AMG 221, an inhibitor of 11b-hydroxysteroid dehydrogenase Type 1. J. Org. Chem. 74(10), 3833-3842 (2009).
251. Courtney R, Stewart PM, Toh M, Ndongo MN, Calle RA, Hirshberg B. Modulation of 11b-hydroxysteroid dehydrogenase (11bHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11bHSD1 inhibitor. J. Clin. Endocrinol. Metab. 93(2), 550-556 (2008).